Treatment with liraglutide — approved to treat type 2 diabetes and obesity — improved non-motor function and the ability to perform daily life activities in people with Parkinson’s disease, according to initial top-line data from a Phase 2 trial. The therapy, sold by Novo Nordisk under the brand names…
AAN 2022
The 2022 Annual Meeting for the American Academy of Neurology is April 2-7 in-person in Seattle and April 24-26 in a virtual format. Parkinson’s News Today is providing coverage from the meeting. Stay tuned to this page for all the latest news.
A three-month community-based boxing program significantly eased motor and non-motor symptoms, as well as depression, in adults with early Parkinson’s disease, a pilot study showed. These preliminary findings support larger and longer studies into the benefits of such programs, which also could include people with more advanced disease. Results were…
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients, new data show. Findings reveal that the vast majority of adverse events (side effects) reported in…
Treatment with oral IPX-203, Amneal Pharmaceuticals’ investigational extended-release carbidopa-levodopa (CD/LD) formulation, reduced “off” time by about 1.5 hours a dose, on average, compared to immediate-release tablets of the medication, according to data from a Phase 3 RISE-PD clinical trial. Top-line results from RISE-PD were announced last year. Detailed…
Recent Posts